Evolus Inc (NAS:EOLS)
$ 12.98 0.05 (0.39%) Market Cap: 812.68 Mil Enterprise Value: 839.25 Mil PE Ratio: 0 PB Ratio: 43.27 GF Score: 55/100

Evolus Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 28, 2021 / 07:20PM GMT
Release Date Price: $7.57 (-2.95%)
Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD

Good afternoon. I am Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Evolus.

We are excited to have with us today David Moatazedi, President and CEO; Lauren Silvernail, Chief Financial Officer; and David Erickson in Investor Relations to discuss the uptake of Jeuveau and also the EU launch in early 2022.

Despite COVID-19, the uptake of Jeuveau and its underlying growth has been very strong, and we continue to expect Jeuveau to be at least the #2 toxin on the market, and for Evolus to expand it's aesthetic offerings to build out a leading aesthetic company over time.

Questions & Answers

Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD

So with that, I wanted to ask you the first question I have for you all. For investors who may be new to the toxin story, can you give us a sense of the size of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot